Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04108195 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT04108195: Active Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.
NCT04108195 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 290 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04108195, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
Primary Outcome
The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Talquetamab
Study Locations (20)
Other
- Universitatsklinikum Freiburg - Freiburg im Breisgau
- Universitaetsklinikum Hamburg Eppendorf - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
- Universitatsklinikum Wurzburg - Würzburg
- VU Medisch Centrum - Amsterdam
- LUMC - Leiden
- Hosp Clinic de Barcelona - Barcelona
- Inst. Cat. Doncologia-H Duran I Reynals - Barcelona
California
- City of Hope National Medical Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- University of California San Francisco - San Francisco
New York
- The Blavatnik Family Chelsea Medical Center at Mount Sinai - New York
- Mount Sinai Medical Center - New York
North Carolina
- Levine Cancer Institute - Charlotte
- Wake Forest Baptist Medical Center - Winston-Salem
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Wisconsin
- Medical College Of Wisconsin - Milwaukee
Alberta
- Arthur J E Child Comprehensive Cancer Centre - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2020-02-21 |
| Est. Completion | 2027-04-07 |
| Phase | Phase 1 |
What the registry record for NCT04108195 still lists
NCT04108195 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Teclistamab is the first listed.
NCT04108195 names 20 study sites across 9 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04108195 about?
NCT04108195 is a clinical study titled "A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma". The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
What is the current status of trial NCT04108195?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2020-02-21. Estimated completion is 2027-04-07.
What conditions does trial NCT04108195 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04108195?
The interventions under investigation include: Teclistamab (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Talquetamab (DRUG).
Who is sponsoring clinical trial NCT04108195?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04108195 being conducted?
This trial has 20 study locations across California, New York, North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04108195's enrollment target sits among peer trials
290 81st of 438 higher than 358 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI